BASEL, Switzerland — Early-stage HealthTech and TechBio founders looking to collaborate with leading pharmaceutical companies now have an opportunity to join one of Europe’s most established life sciences innovation programs. The DayOne Accelerator has officially opened applications for its 2026 cohort, offering startups access to industry expertise, strategic partnerships, and one of the world’s strongest pharmaceutical ecosystems.
Based in Basel, Switzerland, the accelerator focuses on supporting startups developing technologies that can transform pharmaceutical research and development. Since launching in 2018, DayOne has built a reputation for helping founders validate their solutions, connect with major industry players, and accelerate commercialization without taking equity or charging participation fees.
The program is now accepting applications until May 31, 2026.
Building the Future of Pharma Innovation
The DayOne Accelerator is designed specifically for startups working at the intersection of healthcare, biotechnology, and technology. Its mission is to help emerging companies bring innovative solutions into pharmaceutical R&D environments faster by connecting them directly with industry experts, research institutions, investors, and potential partners.
The three-month hybrid program combines mentorship, workshops, networking opportunities, and business development support tailored to the needs of HealthTech and TechBio founders.
Areas of interest include:
- Drug discovery technologies
- Clinical development and trial optimization
- Biomarkers and companion diagnostics
- Data infrastructure for pharmaceutical R&D
- Organ-on-chip and organoid technologies
- Non-animal testing methods
- Laboratory automation
- AI-powered healthcare and clinical trial solutions
- Patient engagement and remote monitoring technologies
- Real-world evidence platforms
- Discovery tools and enabling technology platforms
Unlike many accelerators that focus broadly on healthcare innovation, DayOne specifically targets startups building technologies that can improve how pharmaceutical companies discover, develop, test, and commercialize therapies.
Who Can Apply?
The accelerator welcomes both Swiss and international startups that are actively developing solutions relevant to pharmaceutical R&D.
Eligible companies should:
- Operate in HealthTech or TechBio
- Be at the pre-incorporation, seed, or Series A stage
- Have raised less than $10 million in dilutive funding
- Be interested in collaborating with pharmaceutical companies
- Demonstrate strong innovation potential and scalability
Selected startups receive personalized support designed to strengthen their positioning within the pharmaceutical industry and improve readiness for commercial partnerships and fundraising.
What Participants Receive
One of the program’s strongest differentiators is its equity-free and fee-free structure. Founders can participate without giving up ownership or paying program costs.
Participating startups gain access to:
- One-on-one mentorship from industry experts
- Direct engagement with pharmaceutical companies
- Investor introductions and fundraising support
- Access to Basel’s life sciences ecosystem
- Workshops focused on commercial and regulatory readiness
- Networking opportunities with healthcare innovators and decision-makers
The accelerator’s goal is not only to help startups grow but also to create long-term opportunities for collaboration with pharmaceutical organizations actively seeking innovative technologies.
Beyond the Accelerator: DayOne NEXT
The most promising companies emerging from the accelerator may be invited to join DayOne NEXT, a longer-term growth program designed to support startups as they scale.
Additional benefits can include:
- Up to CHF 50,000 in grant funding
- Up to CHF 50,000 in tailored business services
- Twelve months of office space at Switzerland Innovation Park Basel Area
- Relocation support for international startups
- Access to regional innovation incentives
- Ongoing mentorship and investor introductions
The extended program is designed to help companies establish a long-term presence within the Basel life sciences ecosystem, one of the most important biotech and pharmaceutical hubs globally.
Important Dates for the 2026 Cohort
Applicants should take note of the following timeline:
- March 31 – May 31, 2026: Applications open
- June 25–26, 2026: Selection Days, where 15 startups will be chosen
- September 7–8, 2026: Kickoff Bootcamp in Basel
- December 2026: Innovation Showcase and Demo Event
A Proven Track Record
Since its launch, DayOne has supported more than 128 ventures, including over 60 HealthTech startups focused on pharmaceutical innovation.
Notable alumni include InSilicoTrials, Risklick, TrialHub, Oncoustics, Theremia, and Lemna Bio. The accelerator has become an important catalyst within Basel’s innovation ecosystem, hosting 17 events and attracting more than 3,500 participants during 2025 alone.
As pharmaceutical companies increasingly seek external innovation and startup collaboration, programs like DayOne are becoming critical bridges between emerging technologies and industry adoption.
For founders building solutions that can improve pharmaceutical research, clinical development, or healthcare innovation, the 2026 DayOne Accelerator offers access to expertise, partnerships, and resources that could significantly accelerate growth.
Applications remain open until May 31, 2026.
